PACAP and migraine
- PMID: 40442928
- DOI: 10.1093/brain/awaf131
PACAP and migraine
Abstract
A number of neuropeptides, including pituitary adenylate cyclase-activating polypeptide (PACAP), play an important role in the pathophysiology of migraine. Infusions of PACAP in patients with migraine can provoke migraine attacks. A placebo-controlled study with a monoclonal antibody directed against the PACAP-receptor failed to show efficacy. In a small, short, proof-of-concept study, a monoclonal antibody directed against PACAP (Lu AG09222) showed efficacy in reducing monthly migraine days compared to placebo but failed for the end point 50% reduction in migraine days. The ongoing PROCEED study, a double-blind, placebo-controlled, dose-finding study investigating four different doses of Lu AG09222 versus placebo for migraine prevention, is expected to complete in the second half of 2025.
Keywords: calcitonin gene related peptide (CGRP); migraine; migraine prevention; pituitary adenylate cyclase-activating polypeptide (PACAP).
© The Author(s) 2025. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous